Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Amgen Reports Q2/24 Results – Total Revenue Increase of 20% to US$8.4B

Aug 6, 2024

On 6 August 2024, Amgen announced its financial results for Q2/2024, reporting total revenues increased 20% to US$8.4 billion compared with Q2/2023.  Twelve of its products delivered at least double-digit sales growth in the quarter, including Prolia® (denosumab), Repatha® (evolocumab), Evenity® (romosozumab-aqqg), Tezspire® (tezepelumab-ekko) and Blincyto® (blinatumomab).

Biosimilar highlights for the quarter include the FDA approval of Amgen’s Bkemv® as the first interchangeable biosimilar to Alexion’s Soliris® (eculizumab) in May 2024, initiation of a Ph 3 study in May 2024 to compare efficacy and safety of Amgen’s ABP 234 with Keytruda® (pembrolizumab), and the enrolment of patients in a study evaluating pharmacokinetic similarity of Amgen’s ABP 206 compared with BMS’ Opdivo® (nivolumab).